Abstract Purpose: The aim of the study is to evaluate the effect of a conformal irradiation in short fractionation scheme of 49.5 Gy in 15 fractions in an overall time of 3 weeks, in terms of overall survival (OAS) and progression free survival (PFS) rates in brain glioma patients. Patients and methods: A prospective study was conducted on 54 brain glioma patients and was carried out in the Radiation Oncology Department, South Egypt Cancer Institute, Assiut University during the period from April 2006 till June 2009. Patients were treated by hypofractionated conformal irradiation (49.5 Gy/15 fractions/3 weeks). Results: The median follow up was 23 months (range: 9-39 months). Two-year OAS and PFS rates were 68% and 60%, respectively. In univariate analysis, age >50 years, poor performance status [Karnofasky score of P40-670%], poor neuroperformance status of score III, high-grade tumor [glioblastoma multiforme], and biopsy were all associated with statistically significant reduction in OAS and PFS rates. Multivariate analysis, showed that age >50 years and glioblastoma pathology were the only independent prognostic factors that were associated with poor OAS (p = 0.003 and p = 0.004, respectively), and PFS (p = 0.027 and p = 0.011, respectively). Conclusion: Hypofractionated conformal radiotherapy was as effective as the conventional radiotherapy, with time sparing for patients, and for radiation oncology centers. Hypofractionated radiotherapy may be considered the radiotherapy regimen of choice in clinical practice for patients with gliomas.
Introduction
In patients with brain gliomas, radiation therapy delivered postoperatively has been shown to increase survival by a few months compared to surgery alone [1, 2] with a 5-year survival rate of 46% for irradiated low-grade astrocytoma patients. Approximately 35% of treated patients with high-grade gliomas survive 1 year, but less than 20% will survive 2 years [3] .
As the radiotherapy fails to cure the majority of patients, it should be of short duration and relatively devoid of side effects [4] . Three-dimensional conformal radiotherapy treatment (3D-CRT) planning and delivery has the general goal of conforming the shape of a target volume, and limiting dose to critical normal structures while increasing the tumor dose [5, 6] . 3D-CRT limits the dose to the hypothalamic and pituitary gland, and reduces the risk of developing clinical hypopituitarism [7] . Our study tested the effect of a conformal irradiation in short fractionation scheme of 49.5 Gy in 15 fractions in an overall time of 3 weeks (in terms of OAS and PFS rates), which is biologically equivalent to 60 Gy in fractions of 2 Gy according to the linear quadratic model [8] .
Patients and methods
The current phase II prospective study was conducted on 54 brain glioma patients and was carried out in the Radiation Oncology Department, South Egypt Cancer Institute, Assiut University during the period from April 2006 to June 2009. The basis of sample size was collecting all patients who were eligible during study period. The study included patients with pathologically proven malignant glioma, Karnofsky performance status scale of P40, and residual size after biopsy or subtotal resection 65 cm in all dimensions. Every patient in the study was subjected to history and physical examination including neurological examination, hemogram, chemistry profile, brain MRI, and biopsy. Patients were treated by hypofractionated conformal irradiation with a total dose of 49.5 Gy given in 15 fractions through an overall period of 3 weeks (330 Gy/fraction). Informed consent was obtained for all patients and the treatment decision was approved by institutional review board at our center.
Radiation therapy technique
PTV was delineated on planning CT scan covering the contrast enhanced zone plus 1 cm margin aiming at 49.5 Gy in 15 fractions. Fixation of the patient's head in treatment position was done using a thermoplastic mask after the patient was centralized. Radio-opaque markers were placed over the mask along laser beams over both tragus and midline to identify the reference isocenter. A lateral scout view is obtained, with scan slice thickness of 5 mm. Patients were injected with urographin intravenous contrast, immediately before scanning. CT data were then transferred by cable to the computer treatment planning system, where gross target volume (GTV), clinical target volume (CTV), planning target volume (PTV) and critical structures (lens, optic nerve & chiasm, brain stem, spinal cord) were determined on each slice. Beam's eye view of PTV was used to choose beam directions and to shape fields with appropriate shielding. Dose distributions were then calculated. A 3D plan was done for each patient and was evaluated by isodose distribution in each slice taking into consideration the International Commission on Radiation Units and Measurements (ICRU50) recommendations (heterogeneity should be kept with +7% & À5% of prescribed dose). Dose volume histogram (DVH) was also done where the plan was considered acceptable if 95% of PTV was encompassed by 95% of prescribed tumor dose. Treatment was given isocentrically using a linear accelerator. The field entry points are aligned using laser beams. Individualized customized blocks were made according to the plan & checked at simulator. All patients were treated by photon beams at either 6 or 15 MV. Corticosteroid therapy (Dexamethasone ampoules) was given at a starting dose of 16 mg/day and the dose was adjusted upward or downward to reach the minimum dose necessary to control neurological symptoms.
Statistical analysis
Progression free survival (PFS) was defined as the interval from enrollment of patients to the date of disease progression, or death from any cause or to date of last follow up. Overall survival (OAS) was defined as the interval from enrollment of patients to the date of death from any cause or to date of last follow up. Progression free survival and OAS rates were estimated using Kaplan-Meier method with Graphed Prism program (version 5). The Log-rank test was used to examine differences in PFS and OAS rates. Cox-regression multivariate analysis was done to determine the independent prognostic factors affecting survival. The p-values were double-sided and 60.05 was the level of significance.
Results

Patients' characteristics
This prospective study included 54 patients with brain glioma. Median age was 65 years (range: 30-75 years). Thirty-six patients (66.7%) were males and 18 (33.3%) were females with male to female ratio of 2:1. The majority of our patients had KPS of P40-670% (43 patients; 80%), and presented with manifestations of increased intracranial tension (headache: 42 patients, 78% and vomiting; 38 patients, 70%). Twentynine patients (54%) had neuroperformance status (NPS) of score II, 43 patients (80%) had high grade glioma, 28 patients (52%) showed temporoparietal lesions by imaging, and 29 patients (54%) underwent subtotal resection (Table 1) .
Survival analysis
The median follow up was 23 months (range: 9-39 months). Two-year OAS and PFS rates were 68% and 60%, respectively. Patients with <50 years of age showed 2-year OAS and PFS of 91%, and 77%, respectively compared to 47% (p < 0.001, HR: 4.86, 95% CI: 2.12-11.13) and 44% (p = 0.004, HR: 2.84, 95% CI: 1.40-5.75), respectively, for older patients. For patients with KPS of >70%, 2-year OAS and PFS rates were 100% (for both survival rates), compared to 63% (p = 0.021, HR: 0.28, 95% CI: 0.09-0.82) and 55% (p = 0.037, HR: 0.35, 95% CI: 0.14-0.89), respectively, for patients with KPS between 40% and 70%. The 2-year OAS rates were 100%, 84%, and 26% for patients with NPS of scores I, II, and III, respectively (p < 0.001), while the 2-year PFS rates were 100%, 76%, and 18%, respectively (p 6 0.001). For patients with low grade glioma, 2-year OAS and PFS rates were 100% (for both survival rates), compared to 53% (p < 0.001, HR: 1.99, 95% CI: 0.08-0.51), and 44% ((p < 0.001, HR: 0.26, 95% CI: 0.12-0.58), respectively, for those with high grade glioma. Patients who underwent subtotal resection showed 2-year OAS and PFS rates of 92.5% and 88%, respectively, compared to 41.5% (p < 0.001, HR: 7.6, 95% CI: 3.07-18.84), and 32% (p < 0.001, HR: 5.3, 95% CI: 2.4-11.5), respectively, for biopsied patients (Table 2 and Figs. 1-3) .
Multivariate Cox regression analysis (Table 3) There were minimal side effects to radiation therapy, in the form of a transient worsening of pretreatment symptoms (symptoms of increased ICT), early in the course of irradiation which usually responds to a short term treatment course of corticosteroids.
Discussion
In limited volume radiotherapy, for brain glioma patients, the standard dose is 56-60 Gy in 28-30 fractions [9] . Dose escalation above 60 Gy did not result in any improvement in disease control or survival as shown by Scott et al. [10] . Nakagawa et al. [11] reported 60-90 Gy high dose conformal radiotherapy results of glioblastoma multiforme. The 1-year, 2-year, 5-year, and 10-year overall survival rates were 75%, 42%, 20%, and 15%, respectively. But the high-dose conformal radiotherapy did not improve survival. Therefore, aggressive treatment modalities did not add more benefit to those patients, so a trend to hypofractionated schedule of radiation therapy was considered. Many studies were done on the short course of radiation therapy to GBM like that of Heogler and Davey [12] , and Thomas et al. [13] who tried a palliative radiation therapy course of 30 Gy/6 daily fractions and 30 Gy/10 daily fractions, respectively. The median survival ranged between 4 and 8 months with an acceptable toxicity profile. These results were close to that described in conventional radiation therapy [14, 15] . Hulshof et al. [1] in a prospective randomized trial compared 3 different fractionation schedules in 155 patients with GBM: either 66 Gy/33 fractions (conventional method) versus 40 Gy/8 fractions (5 Gy/fraction), or 28 Gy/4 fractions (7 Gy per fraction), the median survival was 7, 5.6, and 6.6 months, respectively, so no significant difference in survival was noticed among the 3 groups, and the last 2 schedules were well tolerated. These results were confirmed by Chang et al. [16] who reviewed the results of 59 cases of GBM treated with hypofractionated schedule (50 Gy/20 fractions), 2.5 Gy per fraction. Our study tested a hypofractionated schedule of radiation therapy of 49.5 Gy in 15 fractions in an overall time of 3 weeks.
In the present study, the median follow-up was 23 months (range: 9-39 months). The median survival was 33 months, 2-year OAS was 68% and the 2-year PFS was 60%. This is comparable with Kurtman et al. [2] who studied the effect of 3-D conformal radiation therapy in patients with brain gliomas and found that the mean survival was 25.6 ± 2.7 months and the 3 year survival rate was 55%.
Age, performance status, neuroperformance status, tumor type, and extent of surgical resection, were analyzed in the current study, as potential prognostic factors for overall survival and progression free survival. In univariate analysis (Table 2) , age >50 years, poor performance status [KPS score of P40-670%], poor neuroperformance status of score III, high-grade tumor [glioblastoma multiforme], and biopsy were all associated with statistically significant reduction in OAS and PFS rates. This was in agreement with most of the reported studies [2, [17] [18] [19] , where age, performance status and histology, are considered as well known prognostic factors in malignant glioma patients. In a retrospective Turkish study conducted on 60 patients of supratentorial malignant glial tumor, treated between November 1993 and June 1997 [17] , univariate analysis revealed a significant impact of histology, Karnofesky performance status, and age on survival. In another study, the extent of surgical resection was also found to be an important prognostic factor [18] . Therefore, stratification of patients according to prognostic factors might help to determine the optimum treatment for individual patients. In the present study, multivariate analysis (Cox regression model) of the prognostic factors in patients with gliomas, showed that age >50 years and glioblastoma pathology were the only independent prognostic factors that were associated with poor OAS (p = 0.003 and p = 0.004, respectively), and PFS (p = 0.027 and p = 0.011, respectively). This was matched with reported studies, where multivariate analysis showed that age >50 years [18, 19] , and glioblastoma pathology [20] , were associated with poor survival.
In the present study, the 2-year OAS rate of patients with fibrillary astrocytoma, was high (100%). This was matched with most of the reported studies, where the 2-year survival of low grade glioma patients ranged between 87% and 94% [21, 22] . On the other hand, the current study, showed a 2-year OAS of 18% for patients with glioblastoma multiforme. This was consistent with two series, where the 2-year survival rates of 17-20% in irradiated patients with glioblastoma multiforme were reported [3, 11, 17] . However, other studies conducted on patients with glioblastoma multiforme, showed higher 2-year OAS rates which ranged between 26% and 35% [23] [24] [25] [26] . The superior survival rate in these studies may be explained on the ground of different treatment schedules. In one of these studies, hypofractionated dosing schedule using cyberknife stereotactic radiotherapy was used [23] . The other reported studies used radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma patients [24] [25] [26] .
In conclusion, the hypofractionated conformal radiotherapy was found to be as effective as the conventional radiotherapy with no severe adverse effects. However, considering the convenience of the short-course regimen in terms of time sparing for patients, who can be treated in a few days, and the advantage for radiation oncology centers, which are often overloaded by long patient waiting lists, a short-course therapy with the hypofractionated radiotherapy may be considered the radiotherapy regimen of choice in clinical practice for patients with gliomas. LGG, low grade glioma; HGG, high grade glioma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; STR, subtotal resection. 
